Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China

On the evening of June 27, Fosun Pharma announced that it had successively reached cooperation with Amgen on the commercialization licensing of two Amgen's innovative drugs - apromiste tablets (trade name "otailar") and etacetide hydrochloride injection (trade name "parsabiv") in China (excluding Hong Kong, Macao and Taiwan). Aotaixin was approved by the State Food and Drug Administration in August 2021 to treat adult patients with moderate to severe plaque psoriasis who meet the indications of phototherapy or systematic treatment. Up to now, there are about 6.5 million psoriasis patients in China, of which 57.3% are moderate to severe psoriasis patients. Otella is the first and only oral phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of plaque psoriasis in China. Parsabiv, a new calcium sensitive receptor agonist, was approved by the European drug administration and the US Food and Drug Administration in November 2016 and February 2017 for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease undergoing hemodialysis. In China, parsabiv is in the process of listing application. SHPT is one of the common complications in maintenance hemodialysis patients with chronic kidney disease. Among the hemodialysis patients in China, the incidence rate of SHPT is 47%-58%. For the authorization of parsabiv, Fosun Pharma USA, a subsidiary of Fosun Pharmaceutical Holdings, shall pay a down payment of up to US $47million to Kai Pharma, a subsidiary of Amgen holdings, for the licensed products as agreed